Close Menu

NEW YORK – Luminex said Monday that the US Food and Drug Administration has issued an Emergency Use Authorization (EUA) for its Aries SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19.

The assay runs on the FDA-cleared Aries System, a sample-to-answer molecular diagnostic platform that can perform 144 tests per day. It will allow hospital professionals to determine the appropriate course of treatment for patients suspected of having COVID-19 within approximately two hours, Luminex said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.